These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9035061)

  • 1. Study design and statistical analysis of toxicokinetics: a report of JPMA investigation of case studies.
    Igarashi T; Yabe T; Noda K
    J Toxicol Sci; 1996 Dec; 21(5):497-504. PubMed ID: 9035061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
    Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective.
    Krishna G; Urda G; Theiss J
    Environ Mol Mutagen; 1998; 32(2):115-20. PubMed ID: 9776173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Providing toxicokinetic support for reproductive toxicology studies in pharmaceutical development.
    Schwartz S
    Arch Toxicol; 2001 Sep; 75(7):381-7. PubMed ID: 11693177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.
    Dahlem AM; Allerheiligen SR; Vodicnik MJ
    Toxicol Pathol; 1995; 23(2):170-8. PubMed ID: 7569672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Points to be considered for conducting toxicokinetic studies under GLP and for validating analytical methods.
    Yuzuriha T; Aizawa K; Okada J
    J Toxicol Sci; 1996 Dec; 21(5):505-9. PubMed ID: 9035062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey.
    Hammond TG; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Redfern WS; Sullivan AT; Camm AJ
    Cardiovasc Res; 2001 Mar; 49(4):741-50. PubMed ID: 11230973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicokinetics in preclinical evaluation.
    Baldrick P
    Drug Discov Today; 2003 Feb; 8(3):127-33. PubMed ID: 12568782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation. Toxicology Subcommittee of the Association of the British Pharmaceutical Industry.
    Hull RM
    Hum Exp Toxicol; 1995 Mar; 14(3):305-7. PubMed ID: 7779463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whatever happened to cassette-dosing pharmacokinetics?
    Manitpisitkul P; White RE
    Drug Discov Today; 2004 Aug; 9(15):652-8. PubMed ID: 15279848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sparse sampling for assessment of drug exposure in toxicological studies.
    Burtin P; Mentre F; van Bree J; Steimer JL
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):105-11. PubMed ID: 8839683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of conducting function tests in repeated dose toxicity studies in Japan.
    Matsuzawa T; Hashimoto M; Nara H; Yoshida M; Tamura S; Igarashi T
    J Toxicol Sci; 1997 Dec; 22(5):375-82. PubMed ID: 9442447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present status of animal clinical pathology examinations in the Japanese Pharmaceutical Manufacturers Association.
    Matsuzawa T
    Toxicol Pathol; 1992; 20(3 Pt 2):528-33. PubMed ID: 1296286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.
    Monro A
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):41-57. PubMed ID: 8027948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tiered approach to pharmacokinetic studies.
    Wilson AG; Frantz SW; Keifer LC
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):5-11. PubMed ID: 7737041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutical studies, a key to better toxicology.
    Zbinden G
    Xenobiotica; 1988 Jan; 18 Suppl 1():9-14. PubMed ID: 3344592
    [No Abstract]   [Full Text] [Related]  

  • 19. Reasons for monitoring kinetics in safety evaluation studies.
    Hawkins DR; Chasseaud LF
    Arch Toxicol Suppl; 1985; 8():165-72. PubMed ID: 3868346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.